Published in
Oxford University Press, Open Forum Infectious Diseases, 11(9), 2022
DOI: 10.1093/ofid/ofac610
Links
Tools
Long-term evaluation of residual viremia in a clinical trial of dolutegravir plus lamivudine as maintenance treatment for participants with and without prior lamivudine resistance
Journal article published in 2022 by
María Jiménez-González 
,
Rosa De Miguel Buckley,
David Rial-Crestelo,
David Rial Crestelo,
Rocío Montejano,
Adriana Pinto,
María Jimenez-Gonzalez,
Maria Lagarde,
Andrés Esteban-Cantos,
Paula Aranguren-Rivas,
Julen Cadiñanos,
Otilia Bisbal,
Juan Miguel Castro,
Mireia Santacreu-Guerrero,
Laura Bermejo-Plaza
and other authors.
,
Rosa De Miguel Buckley,
David Rial-Crestelo,
David Rial Crestelo,
Rocío Montejano,
Adriana Pinto,
María Jimenez-Gonzalez,
Maria Lagarde,
Andrés Esteban-Cantos,
Paula Aranguren-Rivas,
Julen Cadiñanos,
Otilia Bisbal,
Juan Miguel Castro,
Mireia Santacreu-Guerrero,
Laura Bermejo-Plaza
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Abstract In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224.